MDXG רווח נקי למניה ב-12 החודשים האחרונים mimedx.com
High margins for EpiFix and FDA approvals are driving price action, and this rolling 12-month EPS chart from the GURU.Markets terminal shows the -0.13 mark capturing this metric. While inelastic demand for regenerative medicine ensures business resilience, Medicare regulatory changes and patent disputes create significant risks for MiMedx Group, Inc. (MDXG).
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_MDXG_-_MiMedx-Group-Inc._-_Earnings-per-share-for-the-last-four-quarters "MiMedx Group - רווח נקי למניה (EPS TTM) MDXG (תקופה 04.07.2022 - 14.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת MiMedx Group Inc (MDXG)
Net income per share over the last four quarters measures the actual yield of each security, allowing investors to assess capital allocation efficiency and overall business profitability. Analyzing the EPS TTM annual snapshot confirms the operational resilience of MiMedx Group, Inc., which is supported by high utilization of biopharmaceutical capacities and the planned modernization of therapeutic implant production lines.
